Progress in the development of immunotherapy for the treatment of patients with cancer

S. A. Rosenberg

Research output: Contribution to journalArticle

Abstract

Several recent developments have hallmarked progress in tumour immunology and immunotherapy. The use of interleukin-2 (IL-2) in cancer patients demonstrated that an immunological manipulation was capable of mediating the regression of established growing cancers in humans. The identification of the genes encoding cancer antigens and the development of means for effectively immunizing patients against these antigens has opened important new avenues of exploration for the development of effective active and cell-transfer immunotherapies for patients with cancer.

Original languageEnglish (US)
Pages (from-to)462-475
Number of pages14
JournalJournal of Internal Medicine
Volume250
Issue number6
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Immunotherapy
Neoplasms
Antigens
Patient Transfer
Neoplasm Genes
Therapeutics
Allergy and Immunology
Interleukin-2

Keywords

  • Antigens
  • Cancer
  • Immunotherapy
  • Interleukin-2
  • Melanoma

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Progress in the development of immunotherapy for the treatment of patients with cancer. / Rosenberg, S. A.

In: Journal of Internal Medicine, Vol. 250, No. 6, 2001, p. 462-475.

Research output: Contribution to journalArticle

@article{e07808f536654ef3b6ad163b42f21d4e,
title = "Progress in the development of immunotherapy for the treatment of patients with cancer",
abstract = "Several recent developments have hallmarked progress in tumour immunology and immunotherapy. The use of interleukin-2 (IL-2) in cancer patients demonstrated that an immunological manipulation was capable of mediating the regression of established growing cancers in humans. The identification of the genes encoding cancer antigens and the development of means for effectively immunizing patients against these antigens has opened important new avenues of exploration for the development of effective active and cell-transfer immunotherapies for patients with cancer.",
keywords = "Antigens, Cancer, Immunotherapy, Interleukin-2, Melanoma",
author = "Rosenberg, {S. A.}",
year = "2001",
doi = "10.1046/j.1365-2796.2001.00911.x",
language = "English (US)",
volume = "250",
pages = "462--475",
journal = "Journal of Internal Medicine",
issn = "0954-6820",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Progress in the development of immunotherapy for the treatment of patients with cancer

AU - Rosenberg, S. A.

PY - 2001

Y1 - 2001

N2 - Several recent developments have hallmarked progress in tumour immunology and immunotherapy. The use of interleukin-2 (IL-2) in cancer patients demonstrated that an immunological manipulation was capable of mediating the regression of established growing cancers in humans. The identification of the genes encoding cancer antigens and the development of means for effectively immunizing patients against these antigens has opened important new avenues of exploration for the development of effective active and cell-transfer immunotherapies for patients with cancer.

AB - Several recent developments have hallmarked progress in tumour immunology and immunotherapy. The use of interleukin-2 (IL-2) in cancer patients demonstrated that an immunological manipulation was capable of mediating the regression of established growing cancers in humans. The identification of the genes encoding cancer antigens and the development of means for effectively immunizing patients against these antigens has opened important new avenues of exploration for the development of effective active and cell-transfer immunotherapies for patients with cancer.

KW - Antigens

KW - Cancer

KW - Immunotherapy

KW - Interleukin-2

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=0035665036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035665036&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2796.2001.00911.x

DO - 10.1046/j.1365-2796.2001.00911.x

M3 - Article

C2 - 11902815

AN - SCOPUS:0035665036

VL - 250

SP - 462

EP - 475

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 0954-6820

IS - 6

ER -